Skip to Main Content
Contribute Try STAT+ Today

As drug makers increasingly grapple with other countries over the cost of medicines, the pharmaceutical industry’s trade group is asking the Trump administration to take “urgent action” against two dozen countries over their pricing policies and for engaging in “unfair” practices that threaten intellectual property rights.

In comments filed with the U.S. trade representative, the trade group also made a point of singling out Japan, South Korea, Malaysia, and Canada for various moves that will purportedly cost drug makers large amounts of sales and jeopardize their ability to develop innovative medicines.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.